PDE / ADE · OEL / OEB

Home→PDE/ADE · OEL/OEB Profiles → Arimoclomol→

Arimoclomol PDE report and OEL report profile

Project-specific health-based exposure limit and occupational toxicology assessment support. The agreed scope may include PDE/ADE derivation, OEL derivation and OEB/OHC banding, based on the exact substance form, available evidence and intended product or workplace context.

CAS Registry Number
289893-25-0
Molecular formula
C14H20ClN3O3
Molecular weight
313.78 g/mol
Drug class
Small-molecule therapy for Niemann-Pick disease type Cmechanism-based pharmacological class not established
Mechanism of action
The mechanism(s) by which arimoclomol exerts its clinical effects in patients with Niemann-Pick disease type C is unknown, according to the US prescribing information. Proposed heat-shock-protein/lysosomal effects should not be presented as established clinical mechanism.
Indications / reported uses
  • In combination with miglustat for treatment of neurological manifestations of Niemann-Pick disease type C (NPC) in adults and paediatric patients aged 2 years and older under the US FDA Miplyffa indication

Sources: US FDA prescribing information — Miplyffa · US FDA — Miplyffa approval · FDA product information

View request basketPrefer email? info@toxwriter.com
PDE / ADE derivationOEL derivationOEB / OHC banding
Assessment scope

PDE/ADE and OEL/OEB assessment

ToxWriter provides project-specific support for Arimoclomol PDE/ADE, OEL and OEB/OHC assessments. This combined profile covers the Arimoclomol Permitted Daily Exposure (PDE) report (the Arimoclomol PDE report); Acceptable Daily Exposure (ADE) is the corresponding health-based daily exposure terminology. It also covers the Arimoclomol Occupational Exposure Limit (OEL) report (the Arimoclomol OEL report). PDE/ADE derivation and workplace exposure assessment are distinct scientific outputs; a band is not a numerical OEL.

Assessment may cover

  • PDE/ADE derivation using relevant toxicological evidence, critical effects, a justified point of departure and adjustment factors.
  • OEL derivation considering relevant hazards, exposure route, duration and workplace conditions.
  • OEB/OHC banding where requested and supported by the evidence; an exposure band is not a numerical OEL.
  • Review of substance identity, evidence quality, uncertainty and data gaps.
PDE/ADE, OEL & OEB/OHC regulatory framework

The EMA HBEL guideline informs PDE/ADE assessments in relevant shared-facility contexts. ECHA and HSE sources address workplace exposure limits; NIOSH provides occupational exposure-banding guidance. The applicable framework depends on the assessment question and jurisdiction.